Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension - PubMed (original) (raw)
. 2006 Jun;290(6):H2417-23.
doi: 10.1152/ajpheart.01170.2005. Epub 2006 Jan 13.
Affiliations
- PMID: 16415071
- DOI: 10.1152/ajpheart.01170.2005
Free article
Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension
Justin L Grobe et al. Am J Physiol Heart Circ Physiol. 2006 Jun.
Free article
Abstract
Cardiac remodeling is a hallmark hypertension-induced pathophysiology. In the current study, the role of the angiotensin-(1-7) fragment in modulating cardiac remodeling was examined. Sprague-Dawley rats underwent uninephrectomy surgery and were implanted with a deoxycorticosterone acetate (DOCA) pellet. DOCA animals had their drinking water replaced with 0.9% saline solution. A subgroup of DOCA-salt animals was implanted with osmotic minipumps, which delivered angiotensin-(1-7) chronically (100 ng.kg(-1).min(-1)). Control animals underwent sham surgery and were maintained on normal drinking water. Blood pressure was measured weekly with the use of the tail-cuff method, and after 4 wk of treatment, blood pressure responses to graded doses of angiotensin II were determined by direct carotid artery cannulation. Ventricle size was measured, and cross sections of the heart ventricles were paraffin embedded and stained using Masson's Trichrome to measure interstitial and perivascular collagen deposition and myocyte diameter. DOCA-salt treatment caused significant increases in blood pressure, cardiac hypertrophy, and myocardial and perivascular fibrosis. Angiotensin-(1-7) infusion prevented the collagen deposition effects without any effect on blood pressure or cardiac hypertrophy. These results indicate that angiotensin-(1-7) selectively prevents cardiac fibrosis independent of blood pressure or cardiac hypertrophy in the DOCA-salt model of hypertension.
Similar articles
- Chronic angiotensin blockade with candesartan cilexetil in DOCA/salt hypertensive rats reduces cardiac hypertrophy and coronary resistance without affecting blood pressure.
Fujita H, Takeda K, Miki S, Morimoto S, Kawa T, Uchida A, Itoh H, Nakata T, Sasaki S, Nakagawa M. Fujita H, et al. Hypertens Res. 1997 Dec;20(4):263-7. doi: 10.1291/hypres.20.263. Hypertens Res. 1997. PMID: 9453261 - Lifetime overproduction of circulating Angiotensin-(1-7) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling.
Santiago NM, Guimarães PS, Sirvente RA, Oliveira LA, Irigoyen MC, Santos RA, Campagnole-Santos MJ. Santiago NM, et al. Hypertension. 2010 Apr;55(4):889-96. doi: 10.1161/HYPERTENSIONAHA.110.149815. Epub 2010 Mar 8. Hypertension. 2010. PMID: 20212262 - Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension.
Iglarz M, Touyz RM, Viel EC, Paradis P, Amiri F, Diep QN, Schiffrin EL. Iglarz M, et al. Hypertension. 2003 Oct;42(4):737-43. doi: 10.1161/01.HYP.0000083511.91817.B1. Epub 2003 Jul 14. Hypertension. 2003. PMID: 12860836 - Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system.
Brown L, Duce B, Miric G, Sernia C. Brown L, et al. J Am Soc Nephrol. 1999 Jan;10 Suppl 11:S143-8. J Am Soc Nephrol. 1999. PMID: 9892155 - Attenuation of cardiovascular remodeling in DOCA-salt rats by the vasopeptidase inhibitor, omapatrilat.
Loch D, Hoey A, Brown L. Loch D, et al. Clin Exp Hypertens. 2006 Jul;28(5):475-88. doi: 10.1080/10641960600798754. Clin Exp Hypertens. 2006. PMID: 16820344
Cited by
- Beneficial effects of long-term administration of an oral formulation of Angiotensin-(1-7) in infarcted rats.
Marques FD, Melo MB, Souza LE, Irigoyen MC, Sinisterra RD, de Sousa FB, Savergnini SQ, Braga VB, Ferreira AJ, Santos RA. Marques FD, et al. Int J Hypertens. 2012;2012:795452. doi: 10.1155/2012/795452. Epub 2012 Feb 9. Int J Hypertens. 2012. PMID: 22482038 Free PMC article. - Estrogen therapy, independent of timing, improves cardiac structure and function in oophorectomized mRen2.Lewis rats.
Jessup JA, Wang H, MacNamara LM, Presley TD, Kim-Shapiro DB, Zhang L, Chen AF, Groban L. Jessup JA, et al. Menopause. 2013 Aug;20(8):860-8. doi: 10.1097/GME.0b013e318280589a. Menopause. 2013. PMID: 23481117 Free PMC article. - Angiotensin-(1-7) suppresses the number and function of the circulating fibrocytes by upregulating endothelial nitric oxide synthase expression.
Wang K, Hu X, Du C, Tu S, Zhang F, Xie X. Wang K, et al. Mol Cell Biochem. 2012 Jun;365(1-2):19-27. doi: 10.1007/s11010-012-1223-0. Epub 2012 Mar 29. Mol Cell Biochem. 2012. PMID: 22456996 - Loss of secretin results in systemic and pulmonary hypertension with cardiopulmonary pathologies in mice.
Zaw AM, Sekar R, Mak SOK, Law HKW, Chow BKC. Zaw AM, et al. Sci Rep. 2019 Oct 2;9(1):14211. doi: 10.1038/s41598-019-50634-x. Sci Rep. 2019. PMID: 31578376 Free PMC article. - Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors.
Cook KL, Metheny-Barlow LJ, Tallant EA, Gallagher PE. Cook KL, et al. Cancer Res. 2010 Nov 1;70(21):8319-28. doi: 10.1158/0008-5472.CAN-10-1136. Epub 2010 Sep 13. Cancer Res. 2010. PMID: 20837666 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous